Ken Griffin Champions Oncology, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$4.5 - $5.23 $3,150 - $3,661	700 Added 26.92%	3,300 $17,000
Q1 2024 May 15, 2024	BUY	$4.9 - $6.91 $9,310 - $13,129	1,900 Added 271.43%	2,600 $12,000
Q4 2023 Feb 14, 2024	SELL	$4.56 - $6.59 $2,280 - $3,295	-500 Reduced 41.67%	700 $3,000
Q3 2023 Nov 14, 2023	SELL	$5.2 - $7.32 $31,200 - $43,920	-6,000 Reduced 83.33%	1,200 $7,000
Q2 2023 Aug 14, 2023	BUY	$4.11 - $6.81 $4,521 - $7,491	1,100 Added 18.03%	7,200 $45,000
Q1 2023 May 15, 2023	BUY	$4.0 - $4.67 $6,400 - $7,472	1,600 Added 35.56%	6,100 $24,000
Q4 2022 Feb 14, 2023	SELL	$3.75 - $7.69 $673,500 - $1.38 Million	-179,600 Reduced 97.56%	4,500 $20,000
Q3 2022 Nov 14, 2022	SELL	$7.21 - $9.47 $253,792 - $333,344	-35,200 Reduced 16.05%	184,100 $1.38 Million

5.82M

15K

Ticker CSBR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,522,400
Market Cap $102M
Description
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Techn...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.